Resuscitec

2018-08-21T13:29:55+00:00

private investors, in addition to support from the German Federal Ministry for Education and Research, and the EU

Other investors:

Thomas R. Villinger

ZFHN Partner:

2012

Initial investment:

Resuscitec develops and markets an innovative system for reanimating patients who have suffered cardiac arrest.

Joachim Wilke

Chief Executive

Other investors: private investors, in addition to support from the German Federal Ministry for Education and Research, and the EU

Other investors:

Thomas R. Villinger

ZFHN Partner:

2012

Initial investment:

Resuscitec develops and markets an innovative system for reanimating patients who have suffered cardiac arrest.

Joachim Wilke

Chief Executive

Resuscitec GmbH is a young medical technology company based in Freiburg; its main focus is on the development and marketing of an innovative system for the reanimation of patients who have suffered cardiac arrest.

The system is based on a therapy developed by Prof. Dr. Dr. h.c. Friedhelm Beyersdorf and his team at the University Heart Center in Freiburg-Bad Krozingen. The therapy, called CARL – Controlled Automated Reperfusion of the whole body – makes it possible to successfully reanimate patients even in cases involving prolonged cardiac arrest.

The focus of the therapy, in addition to ensuring patient survival, is above all to prevent neurological damage – in particular brain damage – as a result of the cardiac arrest.

The development of our innovative, high-tech products requires, besides time and comprehensive medical and technological expertise, above all reliable financial partners with experience and the ability to define goals clearly. We are happy to have found such a partner in the Zukunftsfonds Heilbronn!

Joachim Wilke

CEO Resuscitec GmbH

The development of our innovative, high-tech products requires, besides time and comprehensive medical and technological expertise, above all reliable financial partners with experience and the ability to define goals clearly. We are happy to have found such a partner in the Zukunftsfonds Heilbronn!

Joachim Wilke

CEO Resuscitec GmbH

2010
Founding of the company
2012
Approval of about EUR 2.9 million in funding from the German Federal Ministry of Education and Research, through the “KMU-innovativ” program
2012
First round of financing with ZFHN and other private investors
2012
Development and optimization of the CARL therapy through research on animals, development and optimization of the CARL system
2014
Clinical proof-of-concept for the CARL therapy within the framework of an application observation study at the university clinic in Freiburg
2014
Certification of the company in accordance with DIN (German industrial norm) ISO 13485
2016
Second round of financing with ZFHN and other private investors
2016
Approval of EUR 1.5 million in funding from the EU program “Horizon 2020, Fast Track to Innovation Pilot,” for the project CIRDinnova
2017
The company is awarded the Freiburg Innovation Prize.

Resuscitec is a company that makes the world a better place with the therapy and system it has developed, and it has created jobs in the Freiburg region.